Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. [electronic resource]
Producer: 20120723Description: 1849-56 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Bone Neoplasms -- blood
- Desmoplastic Small Round Cell Tumor -- blood
- Female
- Humans
- In Situ Hybridization, Fluorescence
- Insulin-Like Growth Factor I -- metabolism
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Oncogene Proteins, Fusion -- genetics
- Proto-Oncogene Protein c-fli-1 -- genetics
- RNA-Binding Protein EWS -- genetics
- Receptor, IGF Type 1 -- antagonists & inhibitors
- Sarcoma, Ewing -- blood
- Sequence Analysis, RNA
- Time Factors
- Translocation, Genetic
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.